Target Price | $9.71 |
Price | $7.41 |
Potential |
31.10%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Adaptive Biotechnologies Corp 2026 .
The average Adaptive Biotechnologies Corp target price is $9.71.
This is
31.10%
register free of charge
$12.00
61.94%
register free of charge
$7.00
5.53%
register free of charge
|
|
A rating was issued by 8 analysts: 7 Analysts recommend Adaptive Biotechnologies Corp to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Adaptive Biotechnologies Corp stock has an average upside potential 2026 of
31.10%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 178.96 | 212.74 |
5.10% | 18.88% | |
EBITDA Margin | -74.92% | -24.64% |
28.88% | 67.11% | |
Net Margin | -89.18% | -66.22% |
34.13% | 25.74% |
8 Analysts have issued a sales forecast Adaptive Biotechnologies Corp 2025 . The average Adaptive Biotechnologies Corp sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Adaptive Biotechnologies Corp EBITDA forecast 2025. The average Adaptive Biotechnologies Corp EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Adaptive Biotechnologies Corp Analysts have issued a net profit forecast 2025. The average Adaptive Biotechnologies Corp net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.08 | -0.95 |
30.77% | 12.04% | |
P/E | negative | |
EV/Sales | 5.18 |
3 Analysts have issued a Adaptive Biotechnologies Corp forecast for earnings per share. The average Adaptive Biotechnologies Corp EPS is
This results in the following potential growth metrics and future valuations:
Adaptive Biotechnologies Corp...
Analyst | Rating | Action | Date |
---|---|---|---|
Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Scotiabank |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Jan 28 2025 |
BTIG |
Locked
➜
Locked
|
Locked | Dec 18 2024 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
BTIG |
Locked
➜
Locked
|
Locked | Oct 02 2024 |
Analyst Rating | Date |
---|---|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 21 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Scotiabank:
Locked
➜
Locked
|
Feb 13 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jan 28 2025 |
Locked
BTIG:
Locked
➜
Locked
|
Dec 18 2024 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 11 2024 |
Locked
BTIG:
Locked
➜
Locked
|
Oct 02 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.